| Filed On | Filing |
|---|---|
| 16 Oct 2026 | RW |
| 02 Oct 2026 |
Form 4: Macfarlane K. Angela, Director
Granted 55,924 Stock Options (right to buy) |
| 02 Oct 2026 |
Form 4: Spiegel Robert J., Director
Granted 55,924 Stock Options (right to buy) |
| 02 Oct 2026 |
Form 4: Ryan Una S, Director
Granted 55,924 Stock Options (right to buy) |
| 02 Oct 2026 |
Form 4: Marton Laurence, Director
Granted 55,924 Stock Options (right to buy) |
| 15 Sep 2026 |
Form 4: Voll Mark, Chief Financial Officer
Received 80,000 shares as a grant or award |
| 20 Aug 2026 | 8-K: Other Events |
| 13 Aug 2026 |
8-K/A: Results of Operations and Financial Condition
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth |
| 13 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Financial Statements and Exhibits |
| 04 Aug 2026 | 8-K: Other Events |
| 02 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 30 Jun 2026 | S-8 |
| 30 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 24 Jun 2026 |
Form 4: Ryan Una S, Director
Acquired 54,121 shares (Other Transaction) ($225K) · Acquired 43,044 shares (Other Transaction) ($51.3K) |
| 21 May 2026 |
Form 4: Voll Mark, Chief Financial Officer
Bought 25,000 shares ($19.7K) |
| 15 May 2026 | 10-K/A |
| 14 May 2026 | 10-Q |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Apr 2026 | DEF 14A |
Loading...
